- Reuters•12 minutes ago
India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original. India's Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.
- TheStreet.com•2 hours ago
Sales rose 4% and were 2% ahead of expectation on strong sales from core drugs and promising results from new treatments.
- Business Wire•yesterday
New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis
Genentech, a member of the Roche Group , announced today that new data from the OCREVUS™ clinical trial programs will be presented during the 69th American Academy of Neurology Annual Meeting in Boston, Massachusetts.
RHHBY : Summary for ROCHE HLDG LTD SPONS - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||32.07 - 32.44|
|52 Week Range||25.25 - 33.77|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.26|
|Dividend & Yield||1.02 (3.17%)|
|1y Target Est||N/A|